#1 Clinical Trials Search in Europe

Sodium Laurilsulfate

This article discusses the use of Sodium Laurilsulfate in clinical trials for assessing skin barrier function in adults with atopic dermatitis. The study aims to evaluate the effectiveness of a new moisturizer in strengthening the skin barrier compared to other treatments and no treatment. Sodium Laurilsulfate is used as a challenge agent to test the skin’s response to irritants.

Table of Contents

What is Sodium Laurilsulfate?

Sodium Laurilsulfate (also known as Sodium Lauryl Sulfate or SLS) is a chemical compound used in various products, including personal care items and, in this case, as a research tool[1]. In the context of skin research, it serves as a challenge agent, which means it’s used to test how the skin responds to potential irritants[1].

Role in Atopic Dermatitis Research

In this clinical trial, Sodium Laurilsulfate is being used to study the skin barrier function in people with atopic dermatitis (also known as eczema)[1]. Atopic dermatitis is a chronic skin condition characterized by dry, itchy, and inflamed skin. The skin barrier, which normally protects against irritants and moisture loss, is often compromised in people with this condition.

By applying Sodium Laurilsulfate to the skin, researchers can measure how well the skin barrier functions and how it responds to potential irritants. This helps them evaluate the effectiveness of different moisturizers in strengthening the skin barrier[1].

Research Study Details

The study is a randomized controlled trial comparing a new moisturizer (Propyduo®) with other treatments for atopic dermatitis[1]. The treatments being compared are:

  • Propyduo® (the test product)
  • No treatment
  • Propyless® (reference product 1)
  • Canoderm® (reference product 2)

Study Objectives

The main goal of this study is to determine if using the new moisturizer (Propyduo®) for 4 weeks can strengthen the skin barrier more effectively than no treatment or the reference product Propyless®[1].

Secondary objectives include comparing the effects of all treatments on:

  • Resting skin barrier function: How well the skin barrier works when not stressed
  • Skin redness: A sign of inflammation or irritation
  • Irritant reactions: How the skin responds to potential irritants
  • Skin capacitance: A measure of skin hydration
  • Skin pH: The acidity or alkalinity of the skin surface
  • Product consumption: How much of each product is used over the study period

Eligibility Criteria

To participate in this study, individuals must meet certain criteria[1]:

Inclusion Criteria:

  • Age 18 or older
  • History of atopic dermatitis according to UK working party criteria
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Substantial flare-up of atopic dermatitis within the last 6 months
  • Eczema on the volar forearms (the inner part of the forearm)
  • Known or suspected allergies to any of the study products
  • Unwilling to refrain from using other moisturizers during the study
  • Pregnancy, breastfeeding, or plans to become pregnant during the study
  • Recent use of certain medications for atopic dermatitis

Study Measurements

The study will use several methods to assess the skin barrier function and the effects of the treatments[1]:

  • Trans Epidermal Water Loss (TEWL): This measures how much water evaporates from the skin, indicating how well the skin barrier is functioning.
  • Sodium Laurilsulfate (SLS) irritant reactions: This involves applying SLS to the skin and measuring the reaction to assess skin sensitivity.
  • Skin redness assessment: This is done using image analysis to measure changes in skin redness.
  • Capacitance measurements: This assesses skin hydration levels.
  • Skin pH measurements: This measures the acidity or alkalinity of the skin surface.

Potential Benefits and Risks

While this study aims to improve our understanding of atopic dermatitis treatments, it’s important to note that participating in research involves both potential benefits and risks[1]:

Potential Benefits:

  • Access to new moisturizer treatments that may improve skin condition
  • Contributing to the advancement of atopic dermatitis research
  • Regular skin assessments throughout the study

Potential Risks:

  • Skin irritation from the application of Sodium Laurilsulfate
  • Possible allergic reactions to study products
  • Time commitment for study visits and procedures

It’s crucial for potential participants to discuss these factors with their healthcare provider and the study team before deciding to participate in the research.

Aspect Details
Study Type Randomized controlled trial, Phase II
Main Objective Evaluate new moisturizer (Propyduo®) for skin barrier strengthening
Comparisons New moisturizer vs. no treatment, Propyless®, and Canoderm®
Primary Outcome Trans Epidermal Water Loss (TEWL) measurements
Secondary Outcomes Skin redness, irritant reactions, skin capacitance, skin pH, product consumption
Sodium Laurilsulfate Role Challenge agent for testing skin irritation
Treatment Duration 4 weeks
Participant Criteria Adults (≥18 years) with history of atopic dermatitis

FAQ

  • What is the purpose of using Sodium Laurilsulfate in this clinical trial? Sodium Laurilsulfate is used as a challenge agent to test the skin's reaction to irritants. This helps researchers assess the effectiveness of the moisturizers in strengthening the skin barrier.
  • Who can participate in this clinical trial? Participants must be 18 years or older, have a history of atopic dermatitis according to UK working party criteria, and be willing and able to provide informed consent.
  • What are the main objectives of the study? The main objective is to determine if a new moisturizer (Propyduo®) is superior in strengthening the skin barrier compared to no treatment and a reference product (Propyless®) when applied for 4 weeks.
  • How is the skin barrier function measured in this trial? The primary method for measuring skin barrier function is Trans Epidermal Water Loss (TEWL). Other measurements include skin redness, irritant reactions, skin capacitance, and skin pH.
  • Are there any restrictions for participants during the study? Yes, participants must refrain from using prohibited medications, including moisturizers other than those provided in the study. They also cannot have had any treatment with topical corticosteroids or other established topical treatments for atopic dermatitis within the last 6 months prior to screening.

Ongoing Clinical Trials on Sodium Laurilsulfate

  • Study on the Effect of a New Moisturiser with Glycerol and Urea on Skin Barrier in Adults with Atopic Dermatitis

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany

Glossary

  • Atopic Dermatitis: A chronic, itchy skin condition that is common in children but can occur at any age. It is also known as eczema and is characterized by dry, inflamed skin.
  • Trans Epidermal Water Loss (TEWL): A measurement of the amount of water that evaporates through the skin. It is used to assess the effectiveness of the skin's barrier function.
  • Skin Barrier: The outermost layer of the skin that protects against environmental factors and helps retain moisture.
  • Sodium Laurilsulfate: A substance used in this study as a challenge agent to test the skin's reaction to irritants and assess the effectiveness of moisturizers.
  • Moisturizer: A product applied to the skin to prevent or treat dry skin, protect sensitive skin, and improve skin tone and texture.
  • Skin Capacitance: A measurement of the skin's ability to hold an electrical charge, which is related to its moisture content.
  • Skin pH: A measure of how acidic or alkaline the skin's surface is, which can affect its barrier function and overall health.
  • Topical: Referring to a medication or treatment applied directly to the skin.
  • Flare-up: A sudden worsening or increase in severity of a condition, in this case, atopic dermatitis symptoms.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effect-of-a-new-moisturiser-with-glycerol-and-urea-on-skin-barrier-in-adults-with-atopic-dermatitis/